Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New COPD Candidates Could Get Hung Up On Safety Concerns

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA is facing several novel candidates for chronic obstructive pulmonary disease in 2013; those products should expect close scrutiny due to past issues with class safety and new signals in clinical trials.

Advertisement

Related Content

Breo Inverts Traditional Path To COPD Indication For LABA Combinations
Boehringer Ingelheim’s Me-Too Petition Against Generic Spiriva
Novartis Once-Daily COPD Combo Safe, Effective And Ready For Filing – Everywhere But In The U.S.
GSK/Theravance Breathing Easy: Once-Daily COPD Combo Expected To Meet Regulatory Standards
FDA Supersizes Its Order For LABA Safety Studies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005343

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel